Research
OCRA invests more funds into ovarian cancer research than any other public charity.
Read more about Research Read about groundbreaking OCRA-funded research
OCRA's Mission & Impact
Mission & Impact
Our Mission Statement: Ovarian Cancer Research Alliance is dedicated to curing ovarian cancer while improving treatments by advancing innovative science, promoting preventive measures, and advocating for, educating and supporting anyone affected by gynecologic cancers to ensure the best possible care and outcomes.
Results and Milestones
Numbers tell the story of our impact
- Research and Education Funding
- OCRA’s advocacy efforts have helped secure $3.8 billion in federal research and education funding
- $3.8B
- Invested in Science Innovation
- $140M raised and invested in scientific breakthroughs
- $140M
- Individuals Helped Each Year
- Our programs support more than 140,000 individuals annually
- 140K
For each dollar we spend, 81 cents goes to funding critical research and innovative programs
Advancing Research and Fueling Hope
OCRA has both a laser focus and a panoramic view when it comes to the fight against gynecologic cancers.
Center for Public Policy
OCRA has built a team of passionate, dedicated advocates.
Read more about Center for Public Policy Discover our advocacy impact and get involved
Patient Support
In times of adversity, support becomes a beacon of hope.
Read more about Patient Support Learn about our unique programs
OCRA's History of Impact and Innovation
Ovarian Cancer Research Alliance (OCRA) is the oldest and largest ovarian and gynecologic cancer charity in the world. Since its founding in 1994, OCRA has grown into the leading non-government funder of ovarian and related gynecologic cancer research, investing over $140 million in groundbreaking studies. Through innovative education and advocacy efforts, compassionate support programs, and cross-industry collaboration, OCRA is driving progress and pushing the boundaries of what’s possible to improve outcomes for patients and advance research in its quest for a cure.
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued